Crossmark

Optimal treatment selection for hepatocellular carcinoma in the era of immunotherapy

Crossref DOI link: https://doi.org/10.1007/s00535-026-02411-7

Published Online: 2026-04-20

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Chi, Chen-Ta

Huang, Yi-Hsiang https://orcid.org/0000-0001-5241-5425
License Information

Text and Data Mining valid from 2026-04-20

Version of Record valid from 2026-04-20
More Information

Article History

Received: 10 February 2026

Accepted: 7 April 2026

First Online: 20 April 2026

Declarations

:

: The authors declared that there are no conflicts of interest.